Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wiederrecht GJ et al. | Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. | 1995 | Prog Cell Cycle Res | pmid:9552353 |
Tai J et al. | In vivo function of pig islet xenografts in immunosuppressed diabetic mice. | 1995 | Transplant. Proc. | pmid:8539968 |
Felldin M et al. | Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. | 1995 | Transplant. Proc. | pmid:8540032 |
Bersztel A et al. | Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. | 1995 | Transplant. Proc. | pmid:8540095 |
Jonas S et al. | Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. | 1995 | Clin Transplant | pmid:8541635 |
Andoh TF et al. | Functional and structural characteristics of experimental FK 506 nephrotoxicity. | 1995 | Clin. Exp. Pharmacol. Physiol. | pmid:8542679 |
Fukunaga T et al. | Osteogenesis in xenogeneic bone transplantation, using an immunosuppressant. Rabbit-rat experiments. | 1995 | Acta Orthop Scand | pmid:8553828 |
Ryffel B et al. | Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation. | 1995 | Immunopharmacology | pmid:8557519 |
Stillman IE et al. | FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model. | 1995 | Lab. Invest. | pmid:8558840 |
Gjertson DW et al. | The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. | 1995 | Transplantation | pmid:8545861 |
Echigo Y et al. | Effects of cyclosporine and tacrolimus (FK 506) on acute pancreatitis in mice. | 1995 | Arch Surg | pmid:7528496 |
Chaudhuri B et al. | The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506. | 1995 | FEBS Lett. | pmid:7528690 |
Timerman AP et al. | Characterization of an exchange reaction between soluble FKBP-12 and the FKBP.ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. | 1995 | J. Biol. Chem. | pmid:7531689 |
Sandborn WJ et al. | Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. | 1995 | Hepatology | pmid:7528712 |
Richter A et al. | Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. | 1995 | Biochem. Pharmacol. | pmid:7531976 |
Coghlan VM et al. | Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. | 1995 | Science | pmid:7528941 |
Marx SO et al. | Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. | 1995 | Circ. Res. | pmid:7532117 |
Bäckman L et al. | Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. | 1995 | Transplant. Proc. | pmid:7533361 |
Grobecker HF et al. | Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. | 1995 | Clin Exp Pharmacol Physiol Suppl | pmid:9072458 |
Söderdahl G et al. | FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. | 1995 | Transplant. Proc. | pmid:7533362 |
Mor E et al. | Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. | 1995 | Transplant. Proc. | pmid:7533363 |
Hemenway CS et al. | vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. | 1995 | Genetics | pmid:8582630 |
Senninger N et al. | Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. | 1995 | Transplant. Proc. | pmid:7533364 |
Gonschior AK et al. | Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. | 1995 | Ther Drug Monit | pmid:8585114 |
Loss M et al. | Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. | 1995 | Transplant. Proc. | pmid:7533365 |
Büttemeyer R et al. | Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression. | 1995 | Ann Plast Surg | pmid:8585683 |
Lang T et al. | Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. | 1995 | Transplant. Proc. | pmid:7533367 |
Takeda Y et al. | Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. | 1995 | J. Cardiovasc. Pharmacol. | pmid:8587392 |
O'Rourke M et al. | Recovery of delayed-type hypersensitivity following liver transplantation. | 1995 | Transplant. Proc. | pmid:7533369 |
Goodall T et al. | FK506-induced endothelin release by cultured rat mesangial cells. | 1995 | J. Cardiovasc. Pharmacol. | pmid:8587453 |
Gaweco AS et al. | Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. | 1995 | Transplant. Proc. | pmid:7533370 |
Soldin SJ | Receptor (immunophilin-binding) assay for immunosuppressive drugs. | 1995 | Ther Drug Monit | pmid:8588223 |
Armstrong VW et al. | Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. | 1995 | Transplant. Proc. | pmid:7533371 |
Thomson AW et al. | Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. | 1995 | Ther Drug Monit | pmid:8588225 |
Bismuth H | Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. | 1995 | Transplant. Proc. | pmid:7533415 |
Ochiai T et al. | Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. | 1995 | Transplant. Proc. | pmid:7533419 |
Saito S et al. | The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. | 1995 | Transplant. Proc. | pmid:7533420 |
Tashiro H et al. | Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. | 1995 | Transplant. Proc. | pmid:7533421 |
Shirakata Y et al. | The minimum graft size for successful orthotopic partial liver transplantation in the canine model. | 1995 | Transplant. Proc. | pmid:7533422 |
Kumano K et al. | Role of endothelin in FK 506-induced renal hypoperfusion in rats. | 1995 | Transplant. Proc. | pmid:7533423 |
Izutani H et al. | Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. | 1995 | Transplant. Proc. | pmid:7533425 |
Funayama Y et al. | Changes in cell adhesion molecules after small bowel transplantation in rats. | 1995 | Transplant. Proc. | pmid:7533426 |
Laskow DA et al. | Phase II FK 506 multicenter concentration control study: one-year follow-up. | 1995 | Transplant. Proc. | pmid:7533431 |
Hadley S et al. | Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. | 1995 | Transplantation | pmid:7535482 |
Bakhtiar R and Stearns RA | Studies on non-covalent associations of immunosuppressive drugs with serum albumin using pneumatically assisted electrospray ionization mass spectrometry. | 1995 | Rapid Commun. Mass Spectrom. | pmid:7535601 |
Ikeda H and Fujiwara K | Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro. | 1995 | Hepatology | pmid:7535735 |
Grimmond S et al. | Exclusion of the 13-kDa rapamycin binding protein gene (FKBP2) as a candidate gene for multiple endocrine neoplasia type 1. | 1995 | Hum. Genet. | pmid:7535744 |
Jiang H et al. | Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. | 1995 | J. Invest. Dermatol. | pmid:7535825 |
Atkison P et al. | Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. | 1995 | Lancet | pmid:7535875 |
Shaffer D et al. | Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). | 1995 | Transplantation | pmid:7535958 |
Sheppard KE | Cyclosporin A and FK506 are potent activators of proopiomelanocortin-derived peptide secretion without affecting corticotrope glucocorticoid receptor function. | 1995 | J. Neuroendocrinol. | pmid:8748119 |
Dix SP et al. | Re: Severe interaction between methotrexate and a macrolide-like antibiotic. | 1995 | J. Natl. Cancer Inst. | pmid:7563209 |
Kelly PA et al. | Tacrolimus: a new immunosuppressive agent. | 1995 | Am J Health Syst Pharm | pmid:7552894 |
MacDonald AS and Sketris IS | Tacrolimus in transplantation. | 1995 | Am J Health Syst Pharm | pmid:7552906 |
Kawasaki M et al. | [Immunosuppression and the problems in partial liver transplantation]. | 1995 | Nihon Rinsho Meneki Gakkai Kaishi | pmid:8963785 |
Holmes JA and Twentyman PR | The activity of deoxyspergualin in multidrug-resistant cells. | 1995 | Cancer Chemother. Pharmacol. | pmid:7554042 |
Teraoka S et al. | [Present status and problems in clinical application of tacrolimus(FK506)]. | 1995 | Nihon Rinsho Meneki Gakkai Kaishi | pmid:8963787 |
Elitsur Y et al. | FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system. | 1995 | Dig. Dis. Sci. | pmid:7555446 |
Furlan V et al. | Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. | 1995 | Transplantation | pmid:7537398 |
Kobayashi I et al. | Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. | 1995 | Eur. J. Pediatr. | pmid:7556338 |
Mañez R et al. | Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. | 1995 | Transplantation | pmid:7537400 |
Adachi M et al. | IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. | 1995 | FEBS Lett. | pmid:7556630 |
Van Thiel DH et al. | Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. | 1995 | Am. J. Gastroenterol. | pmid:7537444 |
David M et al. | [Occurrence of suspicious changes in cervix cytology in women after liver transplantation]. | 1995 | Geburtshilfe Frauenheilkd | pmid:7557217 |
Woodle ES et al. | FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. | 1995 | Clin Transplant | pmid:7537988 |
Mills RA et al. | Topical FK-506 prevents experimental corneal allograft rejection. | 1995 | Cornea | pmid:7538061 |
[Experimental and clinical studies on the effectiveness of new immunosuppressive agents used in heart transplantation and transplantation-related complications]. | 1995 | Nihon Kyobu Geka Gakkai Zasshi | pmid:7561285 | |
Lee TK et al. | Postoperative selective bowel decontamination prevents gram-negative bacterial translocation in small-bowel graft recipients. | 1995 | J. Surg. Res. | pmid:7538186 |
Asano K et al. | Generation of effector T cells in Hymenolepis nana-infected, FK-506-treated BALB/c mice. | 1995 | Immunol. Lett. | pmid:7590919 |
Galat A and Metcalfe SM | Peptidylproline cis/trans isomerases. | 1995 | Prog. Biophys. Mol. Biol. | pmid:7538221 |
Goldfeld AE et al. | Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. | 1995 | Virology | pmid:7538254 |
Jurim O et al. | Living-donor liver transplantation at UCLA. | 1995 | Am. J. Surg. | pmid:7538267 |
Minamoto A et al. | Suppression of corneal graft rejection by subconjunctival injection of FK-506 in a rat model of penetrating keratoplasty. | 1995 | Jpn. J. Ophthalmol. | pmid:7543958 |
Ueda M et al. | A proposal of FK506 optimal dosing in living related liver transplantations. | 1995 | Transplantation | pmid:7544035 |
Muthukkumar S et al. | Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. | 1995 | Transplantation | pmid:7544036 |
Muraki T et al. | Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. | 1995 | Transplantation | pmid:7544038 |
Ishikawa A et al. | [A case of tacrolimus-induced glucose intolerance following renal allografting]. | 1995 | Hinyokika Kiyo | pmid:7544064 |
Bennett WM | The nephrotoxicity of immunosuppressive drugs. | 1995 | Clin. Nephrol. | pmid:7540121 |
Lochmüller H et al. | Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. | 1995 | Biochem. Biophys. Res. Commun. | pmid:7544122 |
Moro A et al. | Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved in cell infection. | 1995 | EMBO J. | pmid:7540135 |
Deschler DG et al. | Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. | 1995 | Arch. Otolaryngol. Head Neck Surg. | pmid:7544136 |
Zweifach A and Lewis RS | Slow calcium-dependent inactivation of depletion-activated calcium current. Store-dependent and -independent mechanisms. | 1995 | J. Biol. Chem. | pmid:7540169 |
Rouvière-Fourmy N et al. | 1H and 15N assignment of NMR spectrum, secondary structure and global folding of the immunophilin-like domain of the 59-kDa FK506-binding protein. | 1995 | Eur. J. Biochem. | pmid:7544285 |
Brand PL and Brus F | Immunosuppressive drugs and hypertrophic cardiomyopathy. | 1995 | Lancet | pmid:7540240 |
Sakamoto K et al. | A new assay method for immunosuppressants with a tacrolimus (FK506)-like mode of action. | 1995 | J. Antibiot. | pmid:7544337 |
Natazuka T et al. | Immunosuppressive drugs and hypertrophic cardiomyopathy. | 1995 | Lancet | pmid:7540241 |
Dhawan A et al. | Immunosuppressive drugs and hypertrophic cardiomyopathy. | 1995 | Lancet | pmid:7540242 |
Nielsen FT et al. | Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. | 1995 | Nephrol. Dial. Transplant. | pmid:7540737 |
Reichenspurner H et al. | First experience with FK 506 for treatment of chronic pulmonary rejection. | 1995 | Transplant. Proc. | pmid:7540775 |
Yumiba T et al. | Immunosuppressive and diabetogenic effect of FK 506 on pancreatic islet xenotransplantation. | 1995 | Transplant. Proc. | pmid:7540780 |
Matsuo S and Okamoto K | Enhancement of FK-506 activities by ganglioside (GM3) in vivo. | 1995 | Life Sci. | pmid:7545772 |
Jain AB et al. | Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. | 1995 | Transplantation | pmid:7545836 |
Lampen A et al. | Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. | 1995 | Drug Metab. Dispos. | pmid:8689938 |
Bolman RM | Advantage--FK 506: reduced chronic rejection for lung transplant recipients. | 1995 | Ann. Thorac. Surg. | pmid:7545888 |
Keenan RJ et al. | Clinical trial of tacrolimus versus cyclosporine in lung transplantation. | 1995 | Ann. Thorac. Surg. | pmid:7545889 |
Okamoto M et al. | In situ proliferating status of mononuclear cells in rat small bowel grafts. | 1995 | Int J Exp Pathol | pmid:7547442 |
Sakane T et al. | [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions]. | 1995 | Ryumachi | pmid:8594659 |
Platz KP et al. | Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation. | 1995 | Clin Transplant | pmid:7549052 |
Hammond TG and Kind CN | Pancreatic and nephrotoxicity of immunomodulator compounds. | 1995 | Toxicol. Lett. | pmid:8597171 |
Ma J et al. | Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. | 1995 | Biophys. J. | pmid:8599646 |